Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 Variants) associated with hippocampal sclerosis of aging pathology

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 1, 2015, Pages 75-84

  Nelson, Peter T ^a,c   Wang, Wang Xia ^c   Partch, Amanda B ^a,e   Monsell, Sarah E ^f   Valladares, Otto ^a,e   Ellingson, Sally R ^d   Wilfred, Bernard R ^c   Naj, Adam C ^g   Wang, Li San ^a,e   Kukull, Walter A ^f   Fardo, David W ^b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b DrexelUniversity   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Department of Epidemiology and Biostatistics   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer disease; Frontotemporal lobar degeneration (FTLD); Genome wide association study (GWAS); Hippocampal sclerosis; KATP; Progranulin; SUR2

Indexed keywords

3' UNTRANSLATED REGION; ABCC9 GENE; ADULT; AGED; AGING; ARTICLE; CHROMOSOME 12P; CHROMOSOME 17Q; CHROMOSOME 7P; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENOTYPE; GRN GENE; HIPPOCAMPAL SCLEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; RISK ASSESSMENT; SENILE PLAQUE; SINGLE NUCLEOTIDE POLYMORPHISM; TMEM106B GENE; VERY ELDERLY; ALZHEIMER DISEASE; COMPLICATION; FACTUAL DATABASE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HIPPOCAMPUS; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SCLEROSIS; STATISTICS AND NUMERICAL DATA;

ABCC9 PROTEIN, HUMAN; GRN PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN; SIGNAL PEPTIDE; SULFONYLUREA RECEPTOR; TMEM106B PROTEIN, HUMAN;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; DATABASES, FACTUAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; GENOTYPE; HIPPOCAMPUS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCLEROSIS; SULFONYLUREA RECEPTORS;

EID: 84920264284     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000151     Document Type: Article

References (67)

1. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical app roach. Acta Neuropathol 2012;123:1-11
2. Nelson PT, Smith CD, Abner EL, et al. Hippocampal sclerosis of aging: A prevalent and high-morbidity brain disease. Acta Neuropathol 2013; 126:161-77
3. Amador-Ortiz C, Ahmed Z, Zehr C, et al. Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol (Berl) 2007;113:245-52
4. Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol 2007;61: 435-45
5. Neumann M, Sampath u DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-33
6. Lee EB, Lee VM, Trojanowski JQ, et al. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol 2008;115:305-11
7. Nelson PT, Schmitt FA, Lin Y, et al. Hippocampal sclerosis in advanced age: Clinical and pathological features. Brain 2011;134:1506-18
8. Wilson RS, Yu L, Trojanowski JQ, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol 2013;70:1418-24
9. Leverenz JB, Agustin CM, Tsuang D, et al. Clinical and neuropathological characteristics of hippocampal sclerosis: A community-based study. Arch Neurol 2002;59:1099-106
10. Zarow C, Weiner MW, Ellis WG, et al. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav 2012;2:435-42
11. Nelson PT, Abner EL, Schmitt FA, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 2010;20:66-79
12. Brenowitz WD, Monsell SE, Schmitt FA, et al. Hippocampal sclerosis of aging is a key alzheimer's disease mimic: Clinical-pathologic correlations and comparisons with both al zheimer's disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis 2014;39:691-702
13. Pao WC, Dickson DW, Crook JE, et al. Hippocampal sclerosis in the elderly: Genetic an d pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord 2011;25:364-68
14. Dickson DW, Davies P, Bevona C, et al. Hippocampal sclerosis: A common pathologi cal feature of dementia in very old (9 or =80 years of age) humans. Acta Neuropathol 1994;88:212-21
15. Zarow C, Sitzer TE, Chui HC. Understanding hippocampal sclerosis in the elderly: Epidemiology, characterization, and diagnostic issues. Curr Neurol Neurosci Rep 2008;8:363-70
16. Troncoso JC, Kawas CH, Chang CK, et al. Lack of association of the apoE4 allele with hippocampal sclerosis dementia. Neurosci Lett 1996; 204:138-40
17. Rutherford NJ, Carrasquillo MM, Li M, et al. TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 2012;79:717-18
18. Dickson DW,Baker M,Rademakers R. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly Neurodegener Dis 2010 7, 170-74
19. Van Langenhove T, van der Zee J, Van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration-Amyotrophic lateral sclerosis spectrum. Ann Med 2012;44:817-28
20. Mu rray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 2014;128:411-21
21. Nelson PT, Estus S, Abner EL, et al. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 2014;127:825-43
22. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43:436-41
23. Holl ingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-35
24. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: The uniform data set. Alzheimer Dis Assoc Disord 2007;21:249-58
25. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43:436-41
26. Lambert JC, Ibrahim-Verbaas C A, Harold D, et al. Meta-Analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45:1452-58
27. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: A commentary. Neurobiol Aging 1997;18:S91-94
28. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
29. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005;65:1863-72
30. Folstein MF, Folstein SE, McHugh PR. ''Mini-mental state.'' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
31. Nelson PT, Jicha GA, Kryscio RJ, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010;257:359-66
32. Team RC. R: A language and environmen t for statistical computing. Vienna, Austria, 2013
33. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not ''brain aging'': Neuropathological, genetic, and epidemiological human studies. Acta N europathol 2011;121:571-87
34. Satoh JI, Kino Y, Kawana N, et al. TMEM106B expression is reduced in Alzheimer's disease brains. Alzheimers Res Ther 2014;6:17
35. Lu RC, Wang H, Tan MS, et al. TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese. J Neural Transm 2014;121:283-87
36. Lee MJ, C hen TF, Cheng TW, et al. rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the Taiwanese population. Neurodegener Dis 2011;8:216-20
37. Braak H, Braak E. Staging of Alz heimer's diseaseYrelated neurofibrillary changes. Neurobiol Aging 1995;16:271-78
38. Schneider JA, Aggarwal NT, Barnes L, et al. The neuropathology of older persons with and witho ut dementia from community versus clinic cohorts. J Alzheimers Dis 2009;18:691-701
39. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007;62:406-13
40. Tsuang D,Leverenz JB,Lopez OL,et al., APOE 4 increases risk for dementia in pure synucleinopathies JAMA Neurol 2013, 70, 223-28
41. Ferrari R, Hernandez DG, Nalls MA, et al. Frontotemporal dementia and its subtypes: A genome-wide association study. Lancet Neurol 2014;13: 686-99
42. Chou SH, Shulman JM, Keenan BT, et al. Genetic susceptibility for ischemic infarction and arteriolosclerosis based on neuropathologic evaluations. Cerebrovasc Dis 2013;36:181-88
43. Van Deerlin VM, Sl eiman PM, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010;42:234-39
44. Vass R, Ashbridge E, Gese r F, et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol 2011;121:373-80
45. Wood HB. TMEM106B is a susceptibility locus for Ftld. Nat Rev Neurol 2010;6:184
46. Nichols CG, Singh GK, Grange DK. KATP channels and cardiovascular disease: Suddenly a syndrome. Circ Res 2013;112:1059-72
47. Scurr I, Wilson L, Lees M, et al. Cantu syndrome: Report of nine new cases and expansion of the clinical phenotype. Am J Med Gen Part A 2011;155A:508-18
48. Olson TM, Alekseev AE, Morea u C, et al. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med 2007;4:110-16
49. Adebiyi A, McNally EM, Jaggar JH. Sulfonyl urea receptorYdependent and Yindependent pathways mediate vasodilation induced by ATP-sensitive K+ channel openers. Molec Pharm 2008;74:736-43
50. Neltner JH, Abner EL, Baker S, et al. Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain 2014;137:255-67
51. Parsons MJ, Lester KJ, Barclay NL, et al. Replication of genome-wide association studies (GWAS) loci for sleep in the British G1219 cohort. Am J Med Genet B Neuropsychiatr Genet 2013;162B:431-38
52. Allebrandt KV, Amin N, Muller-Myhsok B, et al. A K(ATP) channel gene effect on sleep duration: From genome-wide association studies to function in Drosophila. Mol Psychiatry 2013;18:122-32
53. Moitra K, Dean M. Evolution of ABC transporters by gene duplication and their role in human disease. Biol Chem 2011;392:29-37
54. Beecham GW, Hamilton K, Naj AC, et al. Genome-wide association meta-Analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Gen 2014;10:e1004606
55. Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol 2014;127:811-24
56. Ohta Y, Tremblay C, Schneider JA, et al. Interaction of transactive response DNA binding protein 43 with nuclear factor kappaB in mild cognitive impairment with episodic memory deficits. Acta Neuropathol Commun 2014;2:37
57. Davidson YS, Raby S, Foulds PG, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: Association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol 2011;122:703-13
58. Robinson JL, Geser F, Corrada MM, et al. Neocortical and hippocampal amyloid-beta and tau measures associate with dementia in the oldest-old. Brain 2011;134:3708-15
59. Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet 2008;17: 3631-42
60. van der Zee J, Van Broeckhoven C. TMEM106B a novel risk factor for frontotemporal lobar degeneration. J Molec Neurosci 2011;45: 516-21
61. Mackenzie IR,Neumann M,Baborie A,et al. A harmonized classification system for FTLD-TDP pathology Acta Neuropathol 2011 122, 111-13
62. Bao L, Hadjiolova K, Coetzee WA, et al. Endosomal KATP channels as a reservoir after myocardial ischemia: A role for SUR2 subunits. Am J Physiol 2011;300:H262-70
63. Schwenk BM, Lang CM, Hogl S, et al. The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J 2014;33:450-67
64. Hu F, Padukkavidana T, Vaegter CB, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 2010;68:654-67
65. Brady OA, Zheng Y, Murphy K, et al. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet 2013;22:685-95
66. Lang CM, Fellerer K, Schwenk BM, et al. Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem 2012;287:19355-65
67. Stagi M, Klein ZA, Gould TJ, et al. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Molec Cell Neurosci 2014;61:226-40